Study Demonstrates Performance of SMARTag Platform - - BioPharm International

ADVERTISEMENT

Study Demonstrates Performance of SMARTag Platform


Redwood Bioscience and Catalent Pharma Solutions have announced the results of an in vivo toxicology study, demonstrating that an antibody drug conjugate (ADC) generated using the proprietary SMARTag platform has a better toxicity profile than a conventional ADC. 

The study, conducted in a rat model by Redwood Bioscience compared the effects of a single dose of 6, 20 or 60 mg/kg of a SMARTag ADC conjugated to a cytotoxic payload using the proprietary HIPS chemistry, to an ADC generated with traditional conjugation methods. 

Results showed that the SMARTag ADC was well tolerated and provided statistically significant survival benefits versus the conventional ADC, particularly at high doses where the conventional ADC resulted in mortality. Elevations in liver enzymes and decreases in platelet counts and reticulocytes were also observed with the conventional ADC at 20 and 60mg/kg treatments, whereas these effects were only seen with the highest dose of the SMARTag ADC. In addition the toxicokinetic analysis showed that the SMARTag ADC had greater exposure and longer circulating half-life than the conventional ADC comparator.

Toxicology study results have been published and are available in the Journal of Bioconjugate Chemistry. 

Source: Catalent


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here